Welcome to our dedicated page for JUPITER NEUROSCIENCES news (Ticker: JUNS), a resource for investors and traders seeking the latest updates and insights on JUPITER NEUROSCIENCES stock.
Jupiter Neurosciences, Inc. develops JOTROL™, a patented resveratrol-based platform used in its clinical-stage neuroinflammation pipeline and Nugevia™ consumer longevity products. Company news centers on CNS and rare-disease development, including Parkinson’s disease work, and on commercialization of Nugevia formulations for mitochondrial support, cognitive health and skin vitality.
Recurring updates also cover investor-conference presentations, practitioner and wellness-channel initiatives, advisory-board additions, financing arrangements tied to convertible notes and a standby equity purchase agreement, and Nasdaq listing-compliance matters affecting its common stock.
Jupiter Neurosciences (NASDAQ: JUNS) was invited as the sole company to present progress at a private investor dinner on February 25, 2026 at Mar-a-Lago in Palm Beach. Management will update attendees on Phase IIa Parkinson’s progress, the neuroinflammation pipeline, and commercial execution of Nugevia™.
The event is invitation-only for accredited investors, organized by the Money Channel NYC, and management said it intends to continue direct investor engagement; contact ir@jupiterneurosciences.com for meeting requests.
Jupiter Neurosciences (NASDAQ: JUNS) entered an Omnibus Amendment with YA II PN, Ltd. that defers installment repayments to April 1, 2026 while keeping the $6.0 million core economic financing terms unchanged. The amendment modifies timing and application mechanics only and adds no new pricing, resets, or commitments.
Management says the change aligns capital timing with advancing its Phase II Parkinson’s program and scaling commercial sales of Nugevia (JOTROL resveratrol), which shows ~25% repeat purchases and ~3% returns. The company remains in compliance with its transaction documents.
Jupiter Neurosciences (NASDAQ: JUNS) announced a strategic initiative on January 28, 2026 to expand its Nugevia™ consumer longevity line to support people using GLP-1 weight-loss therapies. The move aligns the company's clinical-stage JOTROL™ platform with a direct-to-consumer longevity business targeting mitochondrial, metabolic, and neuroinflammatory support.
Jupiter cited rising GLP-1 adoption and consumer concerns—including a reported 4,600% spike in searches for “Ozempic face” and reports that significant weight loss may make patients appear up to 5 years older—as rationale for positioning Nugevia™ MND and PWR as complementary products to address related biological stresses.
Jupiter Neurosciences (NASDAQ:JUNS) will present at the 3rd Annual DealFlow Discovery Conference on January 28-29, 2026 at The Borgata Hotel, Casino & Spa in Atlantic City, NJ.
Christer Rosén, Chairman and CEO, will deliver a company presentation and is available for one-on-one investor meetings. Investors can request an investor pass at no cost to attend. More information about the company is available at the company website.
Jupiter Neurosciences (NASDAQ: JUNS) invites investors to an exclusive live webinar on January 6, 2026 at 4:15 p.m. ET, hosted by RedChip Companies. Chairman and CEO Chister Rosén will review Jupiter's resveratrol-based platform JOTROL™, its differentiated bioavailability profile, and plans for an upcoming Phase 2a Parkinson’s disease trial.
The presentation will also cover Jupiter’s dual-path strategy: early commercialization of the Nugevia™ longevity product line and the pharmaceutical development pathway, plus how recent financing supports execution. A live Q&A follows. Registration is free at the RedChip webinar page and questions can be pre-submitted to JUNS@redchip.com.
Jupiter Neurosciences (NASDAQ: JUNS) marked its first full public year by advancing its JOTROL™ program and launching the Nugevia™ consumer brand while strengthening its balance sheet.
Key 2025 milestones: FDA cleared an IND to start a Phase 2a Parkinson’s trial with enrollment planned for early 2026; JOTROL™ showed a reported nine-fold bioavailability plus blood‑brain barrier penetration in preclinical work; Nugevia launched three products with pre-orders and a subscription model; and a strategic financing agreement with Yorkville provides up to $20 million in flexible capital, including an initial pre-paid advance convertible at $1.50.
Jupiter Neurosciences (NASDAQ: JUNS) announced that its management team will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference (NobleCon21) on December 2–3, 2025 in Boca Raton, Florida.
Management will be available for qualified one-on-one investor meetings during the event and investors can schedule meetings by contacting a NobleCon representative or investor relations via JUNS@redchip.com. NobleCon21 is described as a forum for emerging growth companies, investor access, presentations, and networking opportunities.
Jupiter Neurosciences (NASDAQ:JUNS) announced that the FDA cleared its IND to initiate a Phase 2a clinical trial of JOTROL in Parkinson’s disease on November 5, 2025. The clearance enables enrollment for an exploratory Phase 2a study focused on safety and tolerability with secondary PK/PD and biomarker endpoints, and the company expects to begin enrollment in early 2026. Preclinical MPTP-model data showed improved motor endpoints; the company reports its micellar delivery achieves >9-fold higher bioavailability versus traditional resveratrol. Jupiter continues collaboration with Zina Biopharmaceuticals for protocol design and site selection.
Jupiter Neurosciences (NASDAQ: JUNS) entered into financing agreements with an affiliate of Yorkville Advisors providing access to up to $20 million in capital to support its Phase 2 Parkinson’s trial for JOTROL™ and expansion of the Nugevia™ consumer product line. The financing includes a $6 million prepaid advance (initial $4 million funded on Oct 24, 2024) evidenced by convertible promissory notes with a $1.50 fixed conversion price, and a standby equity purchase agreement (SEPA) to sell up to $14 million of common stock over 24 months subject to an effective registration statement. Prepaid advances carry a 7% original issue discount, interest, and 12‑month maturity; SEPA share issuances may be at a 3.0% discount to market. Proceeds will be used for the Phase 2 trial, DTC marketing for Nugevia™, working capital, and general corporate purposes.
Jupiter Neurosciences (NASDAQ:JUNS) has appointed Jean Fallacara, a renowned entrepreneur and neuroscientist, as the third brand ambassador for their consumer longevity supplement line Nugevia™. Fallacara, recognized as one of the "Most Disruptive Entrepreneurs 2023," brings extensive experience in biohacking and biotechnology, including founding Z-Sciences, which was acquired by inTEST Corp in 2021.
Nugevia™ is built on JOTROL™, Jupiter's patented resveratrol-based micellar delivery platform with enhanced bioavailability. The product line includes three formulations: GLO, MND, and PWR, designed to support cellular resilience. This consumer initiative is part of Jupiter's dual-path strategy, targeting the longevity market projected to reach $8 trillion by 2030, while supporting their clinical development programs.